Uveitis Drug Pipeline Analysis Report 2025

The prevalence of uveitis and its associated complications is increasing globally, with the condition occurring in nearly 714 per 100,000 population and accounting for about 25% of all cases of blindness. Further, studies reveal that ongoing inflammation in untreated uveitis and complications linked to this uncontrolled inflammation are likely to be the reason behind 10% of the blindness in the United States. As a result, there is a growing interest in exploring effective treatment options that offer longer-lasting results and prevent vision loss in uveitis patients.

Report Coverage

The Uveitis Drug Pipeline Report by the publisher gives comprehensive insights into uveitis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Uveitis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The uveitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from uveitis.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing uveitis pipeline development activities related to uveitis.

Uveitis Drug Pipeline Outlook

Uveitis refers to an inflammatory disease that involves inflammation of the middle layer of the eye called uvea. The disease can be caused due to infections, idiopathic cases, trauma, and inflammatory diseases. The symptoms can range from redness, pain, and blurry vision to complete vision loss, indicating that prompt treatment is essential to prevent severe complications. Anterior uveitis ranks as the most prevalent type of the condition, comprising nearly 50% of all uveitis cases, whereas posterior uveitis is reported as the least common form.

Uveitis treatment depends on the underlying cause of the disease. Symptom-based treatments typically focus on pain control, inflammation reduction (steroids and nonsteroidal anti-inflammatory drugs (NSAIDs)), and condition-specific treatments. There is an increased emphasis on developing biologic drugs that target specific inflammatory pathways and new classes of small-molecule inhibitors, such as JAK inhibitors, in order to expand treatment options. Further, the rising investment in ophthalmic drug development and advancements in drug delivery technologies are driving the uveitis drug pipeline forward with several highly promising candidates in clinical development.

Uveitis - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of uveitis drug candidates based on several segmentations including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The uveitis therapeutic assessment report covers 50+ drug analyses based on drug classes:

• Corticosteroids
• Immunosuppressants/Immunomodulators
• Biologic Agents (Monoclonal Antibodies)
• Anti-TNF Agents
• Interleukin Inhibitors
• JAK Inhibitors
• Calcineurin Inhibitors
• Anti-VEGF Agents
• Antibiotics and Antivirals
• Small-Molecule Inhibitors

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Uveitis - Pipeline Assessment Segmentation, By Phases

The uveitis report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for uveitis. There are around 109 drugs in phase II for uveitis.

Uveitis - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under uveitis pipeline analysis are corticosteroids, immunosuppressants/immunomodulators, biologic agents, anti-TNF agents, interleukin inhibitors, jak inhibitors, calcineurin inhibitors, anti-VEGF agents, antibiotics and antivirals, and small-molecule inhibitors. The choice of treatment depends on multiple factors including the underlying inflammation and the immune response involved in the condition.

Uveitis Clinical Trials Therapeutic Assessment - Competitive Dynamics

The uveitis drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in uveitis clinical trials:

• Eli Lilly and Company
• Priovant Therapeutics, Inc.
• Bio-Thera Solutions
• ACELYRIN Inc.
• AbbVie
• Allergan
• Lux Biosciences, Inc.
• Novartis Pharmaceuticals
• Amgen

Uveitis - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for uveitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of uveitis drug candidates.

Brepocitinib

Sponsored by Priovant Therapeutics, Inc., brepocitinib is a selective tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor that is being investigated in a Phase 3 clinical trial with around 220 participants having active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).

QLETLI

QLETLI (Adalimumab Injection), Bio-Thera's biosimilar to Humira® is undergoing a Phase 4 post-marketing clinical study comprising around 60 participants suffering from uveitis. This prospective study aims to evaluate the clinical efficacy and safety of the drug for non-infectious uveitis.

Izokibep

Uveitis drug candidate Izokibep is in a Phase 2 study to evaluate its clinical activity against treating active non-infectious, intermediate-, posterior- or pan-uveitis that requires high-dose steroids. Developed by clinical biopharma ACELYRIN Inc., Izokibep is a small protein molecule that binds to interleukin-17A with high affinity, thereby acting as its selective, potent inhibitor.

Laquinimod eye drops

Currently, in Phase 1 of a prospective, single-center phase 1 clinical study, Laquinimod eye drops are under investigation for their safety, tolerability, and distribution in 12 human participants for 2 weeks.

Reasons To Buy This Report

The Uveitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for uveitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into uveitis collaborations, regulatory environments, and potential growth opportunities within uveitis pipeline insights.

Key Questions Answered in the Uveitis Pipeline Insight Report

• Which companies/institutions are leading the uveitis drug development?
• What is the efficacy and safety profile of uveitis pipeline drugs?
• Which company is leading the uveitis pipeline development activities?
• What is the current uveitis commercial assessment?
• What are the opportunities and challenges present in the uveitis drug pipeline landscape?
• What is the efficacy and safety profile of uveitis pipeline drugs?
• Which company is conducting major trials for uveitis drugs?
• Which companies/institutions are involved in uveitis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in uveitis?

This product will be delivered within 3-5 business days.